|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 11/07/14 Cipher Pharmaceuticals Inc 40FR12B 84:13M Merrill Corp-MD/FA |
Document/Exhibit Description Pages Size
1: 40FR12B Registration of Securities of a Canadian Issuer -- HTML 97K
SEA'34 §12(b)
2: EX-99.01 Miscellaneous Exhibit HTML 31K
3: EX-99.02 Miscellaneous Exhibit HTML 376K
4: EX-99.03 Miscellaneous Exhibit HTML 154K
5: EX-99.04 Miscellaneous Exhibit HTML 44K
6: EX-99.05 Miscellaneous Exhibit HTML 61K
7: EX-99.06 Miscellaneous Exhibit HTML 317K
8: EX-99.07 Miscellaneous Exhibit HTML 32K
9: EX-99.08 Miscellaneous Exhibit HTML 32K
10: EX-99.09 Miscellaneous Exhibit HTML 23K
11: EX-99.10 Miscellaneous Exhibit HTML 557K
12: EX-99.11 Miscellaneous Exhibit HTML 28K
13: EX-99.12 Miscellaneous Exhibit HTML 444K
14: EX-99.13 Miscellaneous Exhibit HTML 27K
15: EX-99.14 Miscellaneous Exhibit HTML 29K
16: EX-99.15 Miscellaneous Exhibit HTML 45K
17: EX-99.16 Miscellaneous Exhibit HTML 27K
18: EX-99.17 Miscellaneous Exhibit HTML 264K
19: EX-99.18 Miscellaneous Exhibit HTML 131K
20: EX-99.19 Miscellaneous Exhibit HTML 28K
21: EX-99.20 Miscellaneous Exhibit HTML 28K
22: EX-99.21 Miscellaneous Exhibit HTML 44K
23: EX-99.22 Miscellaneous Exhibit HTML 41K
24: EX-99.23 Miscellaneous Exhibit HTML 25K
25: EX-99.24 Miscellaneous Exhibit HTML 344K
26: EX-99.25 Miscellaneous Exhibit HTML 169K
27: EX-99.26 Miscellaneous Exhibit HTML 29K
28: EX-99.27 Miscellaneous Exhibit HTML 29K
29: EX-99.28 Miscellaneous Exhibit HTML 40K
30: EX-99.29 Miscellaneous Exhibit HTML 27K
31: EX-99.30 Miscellaneous Exhibit HTML 35K
32: EX-99.31 Miscellaneous Exhibit HTML 351K
33: EX-99.32 Miscellaneous Exhibit HTML 174K
34: EX-99.33 Miscellaneous Exhibit HTML 28K
35: EX-99.34 Miscellaneous Exhibit HTML 28K
36: EX-99.35 Miscellaneous Exhibit HTML 41K
37: EX-99.36 Miscellaneous Exhibit HTML 23K
38: EX-99.37 Miscellaneous Exhibit HTML 23K
39: EX-99.38 Miscellaneous Exhibit HTML 24K
40: EX-99.39 Miscellaneous Exhibit HTML 28K
41: EX-99.40 Miscellaneous Exhibit HTML 406K
42: EX-99.41 Miscellaneous Exhibit HTML 173K
43: EX-99.42 Miscellaneous Exhibit HTML 45K
44: EX-99.43 Miscellaneous Exhibit HTML 40K
45: EX-99.44 Miscellaneous Exhibit HTML 42K
46: EX-99.45 Miscellaneous Exhibit HTML 29K
47: EX-99.46 Miscellaneous Exhibit HTML 28K
48: EX-99.47 Miscellaneous Exhibit HTML 310K
49: EX-99.48 Miscellaneous Exhibit HTML 32K
50: EX-99.49 Miscellaneous Exhibit HTML 32K
51: EX-99.50 Miscellaneous Exhibit HTML 559K
52: EX-99.51 Miscellaneous Exhibit HTML 27K
53: EX-99.52 Miscellaneous Exhibit HTML 424K
54: EX-99.53 Miscellaneous Exhibit HTML 26K
55: EX-99.54 Miscellaneous Exhibit HTML 264K
56: EX-99.55 Miscellaneous Exhibit HTML 156K
57: EX-99.56 Miscellaneous Exhibit HTML 29K
58: EX-99.57 Miscellaneous Exhibit HTML 29K
59: EX-99.58 Miscellaneous Exhibit HTML 44K
60: EX-99.59 Miscellaneous Exhibit HTML 28K
61: EX-99.60 Miscellaneous Exhibit HTML 35K
62: EX-99.61 Miscellaneous Exhibit HTML 32K
63: EX-99.62 Miscellaneous Exhibit HTML 33K
64: EX-99.63 Miscellaneous Exhibit HTML 29K
65: EX-99.64 Miscellaneous Exhibit HTML 33K
66: EX-99.65 Miscellaneous Exhibit HTML 340K
67: EX-99.66 Miscellaneous Exhibit HTML 195K
68: EX-99.67 Miscellaneous Exhibit HTML 29K
69: EX-99.68 Miscellaneous Exhibit HTML 29K
70: EX-99.69 Miscellaneous Exhibit HTML 46K
71: EX-99.70 Miscellaneous Exhibit HTML 354K
72: EX-99.71 Miscellaneous Exhibit HTML 202K
73: EX-99.72 Miscellaneous Exhibit HTML 29K
74: EX-99.73 Miscellaneous Exhibit HTML 29K
75: EX-99.74 Miscellaneous Exhibit HTML 44K
76: EX-99.75 Miscellaneous Exhibit HTML 23K
77: EX-99.76 Miscellaneous Exhibit HTML 369K
78: EX-99.77 Miscellaneous Exhibit HTML 32K
79: EX-99.78 Miscellaneous Exhibit HTML 32K
80: EX-99.79 Miscellaneous Exhibit HTML 23K
81: EX-99.80 Miscellaneous Exhibit HTML 425K
82: EX-99.81 Miscellaneous Exhibit HTML 32K
83: EX-99.82 Miscellaneous Exhibit HTML 32K
84: EX-99.83 Miscellaneous Exhibit HTML 22K
Exhibit 99.29
99.29 News Release Dated September 19, 2013
Cipher’s Partner Ranbaxy receives Paragraph IV Certification
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Sept. 19, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher”) today announced that its sales and distribution partner, Ranbaxy Laboratories Inc. (“Ranbaxy”) has received a Paragraph IV Certification Notice of filing from Watson Laboratories Inc. of an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) for a generic version of Absorica™ (isotretinoin capsules).
Ranbaxy and Cipher intend to vigorously defend Absorica’s intellectual property rights and pursue all available legal and regulatory pathways in defense of the product. Absorica is currently protected by two issued patents listed in the FDA’s Approved Drug Products List (Orange Book), which expire in September 2021. Ranbaxy shall take appropriate actions in response to the Paragraph IV notice letter, and FDA approval of the ANDA shall then be governed by the Hatch-Waxman Act.
Absorica was approved by the FDA in May 2012, and granted a three-year market exclusivity period, which expires in May 2015.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since Cipher was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed six marketing partnerships, generating growing licensing revenue.
Forward-Looking Statements
Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective”, “hope” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company’s Annual Information Form and other filings with Canadian securities regulatory authorities. These factors include, but are not limited to; the applicability of patents and proprietary technology; possible patent litigation; approval of products in the Company’s pipeline; marketing of products; meeting projected drug development timelines and goals; product liability and insurance; dependence on strategic partnerships and licensees; concentration of the Company’s revenue; substantial competition and rapid technological change in the pharmaceutical industry; the publication of negative results of clinical trials of the Company’s products; the ability to access capital; the ability to attract and retain key personnel; changes in government regulation or regulatory approval processes; dependence on contract research organizations; third party reimbursement; the success of the Company’s strategic investments; the achievement of development goals and time frames; the possibility of shareholder dilution; market price volatility of securities; and the existence of significant shareholders. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.
SOURCE Cipher Pharmaceuticals Inc.
Craig Armitage
Investor Relations
TMX Equicom
(416) 815-0700 ext 278
(416) 815-0080 fax
carmitage@tmxequicom.com
Larry Andrews
President and CEO
Cipher Pharmaceuticals
(905) 602-5840 ext 324
(905) 602-0628 fax
landrews@cipherpharma.com
| This ‘40FR12B’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/7/14 | F-X | ||
| 9/19/13 | ||||
| List all Filings | ||||